[A combination chemotherapy with cytarabine ocfosfate, low dose etoposide, and G-CSF for the treatment of high risk MDS (RAEB, RAEBt)--a pilot study].
We evaluated a combination chemotherapy with cytarabine ocfosfate (SPAC), low dose etoposide and G-CSF for the treatment of high-risk MDS (RAEB, RAEBt). Seven patients with high-risk MDS were treated with a daily combination, 200 mg/day SPAC p.o., 50 mg/day etoposide p.o. and 75 micrograms/day G-CSF s.c. One patient achieved complete response, 2 achieved good response and one patient minor response. Although all of the patients developed severe marrow hypoplasia after chemotherapy, the nonhematologic adverse effects were mild enough to be tolerated. This combination chemotherapy should be useful in the clinical management of patients with high-risk MDS.
Hara
M
M
Division of Hematology and Internal Medicine, Ehime Prefectural Central Hospital.
Kojima
K
K
Azuma
T
T
Narumi
H
H
Shinagawa
K
K
D000368:Aged; D000754:Anemia, Refractory, with Excess of Blasts / Q000188:drug therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000627:therapeutic use; D001088:Arabinonucleotides / Q000008:administration & dosage; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D003568:Cytidine Monophosphate / Q000008:administration & dosage / Q000031:analogs & derivatives; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012306:Risk
D001088:Arabinonucleotides; D016179:Granulocyte Colony-Stimulating Factor; C061162:1-arabinofuranosylcytosine-5'-stearylphosphate; D005047:Etoposide; D003568:Cytidine Monophosphate